About Akeso, Inc.
Akeso, Inc. is a Chinese biopharmaceutical company founded in 2012 in Zhongshan, Guangdong province, dedicated to the research, development, manufacture and commercialisation of innovative biological medicines. The company is listed on the Hong Kong Stock Exchange and has specialised in bispecific antibodies and next-generation immuno-oncology therapies.
Its products approved in China include cadonilimab, the world's first marketed PD-1/CTLA-4 bispecific antibody; ivonescimab, a PD-1/VEGF bispecific licensed internationally to Summit Therapeutics with closely watched Phase III results; penpulimab (anti-PD-1); and products in metabolic and inflammatory areas such as ebronucimab (PCSK9) and ebdarokimab (IL-12/23). Its proprietary Tetrabody platform supports a pipeline of more than 50 programmes across oncology, autoimmunity, inflammation and metabolism.
Akeso integrates discovery, clinical development and GMP manufacturing at its Zhongshan facilities, with subsidiaries and clinical activity in the United States, Australia and other countries. For international partners, it is one of China's reference biopharmaceutical companies in bispecific antibodies, with globally licensed assets and headquarters by the Torch Development Zone in Zhongshan.
Its products approved in China include cadonilimab, the world's first marketed PD-1/CTLA-4 bispecific antibody; ivonescimab, a PD-1/VEGF bispecific licensed internationally to Summit Therapeutics with closely watched Phase III results; penpulimab (anti-PD-1); and products in metabolic and inflammatory areas such as ebronucimab (PCSK9) and ebdarokimab (IL-12/23). Its proprietary Tetrabody platform supports a pipeline of more than 50 programmes across oncology, autoimmunity, inflammation and metabolism.
Akeso integrates discovery, clinical development and GMP manufacturing at its Zhongshan facilities, with subsidiaries and clinical activity in the United States, Australia and other countries. For international partners, it is one of China's reference biopharmaceutical companies in bispecific antibodies, with globally licensed assets and headquarters by the Torch Development Zone in Zhongshan.